boehringer glp 1 glp-1-dual-agonist-survodutide-weightloss-obesity-overweight-improvement Boehringer moves Wegovy competitor into

Why it matters now: if list prices compress toward $150, access parity rises and the competitive moat shifts from drug arbitrage to care integration

In a phase three trials, patients saw a major weight reduction of nearly 16.6% of their body weight after 64 weeks

Newer drugs like semaglutide and tirzepatide can lead to significant weight loss, but often cause stomach issues like nausea, vomiting, diarrhea, or constipationespecially at the start

Alternatively, a hydroxyapatite toothpaste like Boka or RiseWell provides remineralization support without requiring fluoride, though fluoride remains the most evidence-backed option for cavity prevention